http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20050087886-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a475ef11f7bebdacf7d47b557dabdada
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
filingDate 1996-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe6b419c8b4efaf6763308e83a12e4e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0a47c7194fb9ac5df0ec389dfdb79b7
publicationDate 2005-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-20050087886-A
titleOfInvention Modified release oral pharmaceutical composition containing 5-asa and method for the treatment of bowel diseases
abstract The present invention provides pharmaceutical compositions of altered release properties for treating Crohn's disease and inflammatory bowel disease (IBD), such as ulcerative colitis, wherein the composition of the present invention is 5-aminosalicylic acid (5-ASA) as an active ingredient. And, by means of releasing an appropriate amount of 5-ASA in the small and large intestine, to obtain clinically important ubiquitous effect characteristics and for targeted release.
priorityDate 1995-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534865
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393321
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16666
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556620
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID455787888
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4075

Total number of triples: 35.